Abstract
Background:
An estimated 55.5% and 37.3% of people globally with type 2 diabetes (T2D) will have concomitant non-alcoholic fatty liver disease (NAFLD) and the more severe fibroinflammatory stage, non-alcoholic steatohepatitis (NASH). NAFLD and NASH prevalence is projected to increase exponentially over the next 20 years. Bayesian Networks (BNs) offer a powerful tool for modelling uncertainty and visualising complex systems to provide important mechanistic insight.
Methods:
We applied BN modelling and probabilistic reasoning to explore the probability of NASH in two extensively phenotyped clinical cohorts: 1) 211 participants with T2D pooled from the MODIFY study & UK Biobank (UKBB) online resource; and 2) 135 participants without T2D from the UKBB. MRI-derived measures of visceral (VAT), subcutaneous (SAT), skeletal muscle (SMI), liver fat (MRI-PDFF), liver fibroinflammatory change (liver cT1) and pancreatic fat (MRI-PDFF) were combined with plasma biomarkers for network construction. NASH was defined according to liver PDFF >5.6% and liver cT1 >800ms. Conditional probability queries were performed to estimate the probability of NASH after fixing the value of specific network variables.
Results:
In the T2D cohort we observed a stepwise increase in the probability of NASH with each obesity classification (normal weight: 13%, overweight: 23%, obese: 36%, severe obesity: 62%). In the T2D and non-T2D cohorts, elevated (vs. normal) VAT conferred a 20% and 1% increase in the probability of NASH, respectively, while elevated SAT caused a 7% increase in NASH risk within the T2D cohort only. In those with T2D, reducing HbA1c from the ‘high’ to ‘low’ value reduced the probability of NASH by 22%.
Conclusion:
Using BNs and probabilistic reasoning to study the probability of NASH, we highlighted the relative contribution of obesity, ectopic fat (VAT and liver) and glycaemic status to increased NASH risk, namely in people with T2D. Such modelling can provide insights into the efficacy and magnitude of public health and pharmacological interventions to reduce the societal burden of NASH.
1 Introduction
According to the World Health Organisation, the global prevalence of obesity almost tripled between 1975 and 2016 with 39% of the world’s adult population (1.9 billion; 39% of men, 40% of women) overweight and 13% (650 million; 11% of men, 15% of women) living with obesity in 2016 (). In parallel, according to the International Diabetes Federation, the global diabetes prevalence in 2019 was estimated to be 9.3% (463 million people), with a projected 25% increase by 2030 (10.2% prevalence; 578 million) and a projected 50% increase (10.9% prevalence, 700 million) by 2045 ().
People living with obesity and type 2 diabetes (T2D) are at a significantly greater risk of liver related complications compared to people without either condition (). Notably, according to a recent global meta-analysis and meta-regression, ~55.5% of people with T2D worldwide have associated non-alcoholic fatty liver disease (NAFLD), 37.3% non-alcoholic steatohepatitis (NASH) and 17.3% biopsy-confirmed advanced liver fibrosis (). Those people with NAFLD and concomitant T2D have significantly worse liver-related outcomes including higher rates of advanced fibrosis, cirrhosis and liver-related cancers compared to those with NALFD only (–).
20-year projections of the economic and clinical burden of NASH/NAFLD estimate that co-prevalent NASH and T2D will account for 65,000 liver transplants, 812,000 liver-related deaths and 1.37 million cardiovascular-related deaths, totalling $55.8 billion in healthcare costs (). Early detection of those patients with T2D at high-risk of NASH is therefore of considerable importance and would enable early access to personalised care/medicines and improved clinical and disease outcomes.
In both T2D and NASH, obesity is a significant risk factor, though the clinical utility of the body mass index (BMI) metric is limited since it describes global body mass relative to height and does not describe body fat distribution. People with T2D represent a clinical population, and relative to those without T2D, are characterised by a distinct body composition profile with significantly higher volumes of visceral adipose tissue (VAT), increased liver fat deposition and fibroinflammation and reduced skeletal muscle mass (, ), when measured by magnetic resonance imaging (MRI). Furthermore, elevated VAT but not subcutaneous adipose tissue (SAT), has been associated with a significant increase in circulating insulin, plasma glucose and incidence of the metabolic syndrome (, ), highlighting the importance of studying body fat distribution.
Multi-parametric MRI can provide quantitative tissue characterisation in multiple organs. Fat infiltration (steatosis), iron deposition and fibroinflammatory change can be measured using proton density fat fraction (PDFF), iron and fat corrected T1 mapping (cT1) with MRI. PDFF quantifies liver fat at each voxel and correlates strongly with histologic steatosis (, ) while liver cT1, an indicator of liver disease activity and severity, correlates strongly with histological markers of fibroinflammation and demonstrates high diagnostic accuracy for stratifying patients with NASH and those with at-risk NASH (, ).
In this paper, we use MRI-derived measures of body composition and liver health using PDFF and liver cT1 to identify participants with NAFLD and NASH and to overcome the intrinsic limitation of the BMI noted above by exploring regional fat distribution. We describe how applying Bayesian-networks to study the associations between MRI-derived measures of body composition and liver health, enables a comprehensive assessment of the high-risk metabolic phenotypes associated with co-prevalent T2D and NASH. We also show how BNs can be used to identify potential therapeutic targets for alleviating NASH risk.
2 Methods
2.1 Data collection and preparation
We investigated two datasets: the first included 221 participants with T2D pooled from the MODIFY study (NCT04114682) () and the UK Biobank (UKBB) online resource under application 9914. MODIFY recruited participants with T2D from primary or secondary care settings from three sites across the UK; UKBB is a general population-based cohort study in people aged 40 to 69 years from across the UK (https://www.ukbiobank.ac.uk/). The second cohort included 135 participants without diabetes of any kind (non-T2D) drawn from the UKBB. All participants underwent an abdominal MR scan that included multi-parametric imaging of the liver and pancreas. See () for an in-depth description of the MR-protocol.
2.2 Clinical details and MRI image acquisition and analysis
Body composition was examined from a 2D MR slice positioned at the third lumbar (L3) vertebra and measurements of VAT, SAT and skeletal muscle were based on manual delineations by trained analysts, see Figure 1. Measures of skeletal muscle were then indexed to the participant’s height to produce a measure of skeletal muscle index (SMI) (cm2/m2). All continuous variables were discretized based on pre-defined clinical thresholds or by splitting the data into ‘low’ and ‘high’ value groups determined at the 75th percentile value, see supplementary. For example, HbA1c within the T2D cohort was discretised by splitting the cohort into ‘low’ (HbA1c <62mmol/mol) and ‘high’ (HbA1c >=62mmol/mol) value groups. Presence of NASH was classified based on liver PDFF >5.6% and liver cT1 >800ms. Such thresholds have consistently demonstrated high diagnostic accuracy for stratifying patients with NASH, predicting liver-related outcomes, classifying between NASH and NAFLD only and are an effective alternative to liver biopsy for diagnosing NASH (, ).
Figure 1
Bayesian-networks (see Supplementary information for full explanation of BNs)
Bayesian Networks (BNs) are directed acyclic graphs that are capable of explicitly representing and analysing complex systems and under certain assumptions, specifying causal relationships. When combined with probabilistic reasoning, BNs can be used to estimate the probability of an ‘event’ occurring in response to a fixed evidence input. For example (), used BNs to estimate the probability of acute kidney injury after fixing certain biochemical abnormalities in patients with gastrointestinal cancer.
To investigate the probability of NASH in specific clinical characteristics, we conducted conditional probability queries that estimate the probability of an event (here, NASH), given an ‘evidence list’ containing the set values of specific network variables (for example, obesity or HbA1c status). The probability of NASH was estimated using the likelihood weighting algorithm, a Monte Carlo approximation technique utilising importance sampling. While BNs can be extended to incorporate a plethora of clinical features and sources of information, our networks have been deliberately limited to illustrate their application of the present analysis.
2.3 Network variables
BN construction included the following variables: liver fat (PDFF %), liver cT1 (ms), pancreatic fat (PDFF %) visceral adipose tissue (cm2), subcutaneous adipose tissue (SAT) (cm2), skeletal muscle (SMI) (cm2), gender (1[male]/0[female]), BMI (kg/m2), age (yrs), HbA1c (mmol/mol), AST (IU/L), ALT (IU/L), smoking status (0[non-smoker]/1[current smoker]/2[past smoker]).
2.4 Bayesian-network construction (See Supplementary information for full overview of network construction)
BN construction and probabilistic inference were completed using the ‘bnlearn’ package and visualised using ‘graphviz’ within the R software platform (version 3.6.1). Automated network structures, derived from a score-and-search algorithm (), were adjusted by removing or reversing nonsensical edges and inserting edges based on domain knowledge gleaned from medical literature. Crucially, incorporation of clinical knowledge in these network structures enables the modelling of causal relationships between variables. Figures 2, 3 show the final networks from the T2D and non-T2D cohorts, respectively.
Figure 2
Figure 3
2.5 Statistical analysis
All statistical analyses used the R software platform (version 3.6.1). Descriptive statistics, showing median [inter quartile range], are reported to summarise population characteristics. Wilcoxon and X2 tests were used to make between group comparisons.
3 Results
3.1 Descriptive characteristics of participants
The baseline clinical, biochemical, and imaging characteristics are shown in Table 1. The groups were well matched for age, gender, and BMI. Despite similar liver biochemistry, participants from the T2D cohort (and thus higher HbA1c (<0.001)) had significantly elevated liver cT1 (<0.001), liver PDFF (<0.001), VAT/SAT ratio (p=0.034) and greater prevalence of NASH (<0.001).
Table 1
| Characteristic | T2D (n = 221) | Non-T2D (n = 135) | p-value |
|---|---|---|---|
| Clinical data | |||
| Age (yrs) | 57 [52-64] | 57 [53-63] | 0.3 |
| Sex (n of male participants [%]) | 146 (66%) | 98 (73%) | 0.2 |
| BMI (kg/m2) | 30 [27-34] | 29 [26-33] | 0.3 |
| HbA1c (mmol/mol) | 50 [41-62] | 36 [33-38] | <0.001 |
| AST (IU/L) | 24 [19-29] | 27 [23-32] | <0.001 |
| ALT (IU/L) | 27 [20-36] | 26 [19-35] | 0.5 |
| MRI data | |||
| Liver cT1 (ms) | 751 [695-827] | 709 [672-752] | <0.001 |
| Liver fat (%) | 8 [4-14] | 5 [3-11] | <0.001 |
| Pancreatic fat (%) | 5 [3-9] | 5 [3-8] | 0.6 |
| VAT (cm2) | 238 [173-307] | 215 [149-279] | 0.065 |
| SAT (cm2) | 249 [180-322] | 271 [181-366] | 0.3 |
| VAT/SAT ratio | 0.90 [0.58-1.33] | 0.79 [0.57-1.15] | 0.034 |
| SMI (cm2/m2) | 49 [42-56] | 51 [43-56] | 0.6 |
| NASH (n of participants [%]) | 69 (31%) | 13 (9%) | <0.001 |
Baseline characteristics of T2D and non-T2D cohorts.
Data is median [IQR]. Bold denotes significance.
3.2 Estimation of NASH using probabilistic reasoning
The baseline probabilities of NASH in the T2D and non-T2D cohorts were 30% and 10%, respectively. ‘Intervening’ on a variable within the BN means that a specific value is assigned to it. For example, the variable ‘HbA1c’ may be assigned the values ‘0’ (‘low’ value) or ‘1’ (‘high’ value). The effect of amending level of glucose regulation is then propagated throughout the network, where the variables(s) conditionally dependent on the intervened variable(s) are updated to reflect the specified evidence.
3.3 T2D cohort
3.3.1 Impact of body mass index
We first explored the effect of obesity status on NASH risk, observing a 13%, 23%, 36% and 62% probability of NASH under normal weight (<25kg/m2), overweight (25-30kg/m2), obesity (30-40kg/m2), and severe obesity (>40kg/m2) settings, respectively. This equated to a 23% greater probability of NASH when comparing ‘obesity’ vs. ‘normal weight’. (Table 2; Figure 4).
Table 2
| Biomarker | Cohort | |
|---|---|---|
| T2D (n = 221) | Non-T2D (n = 135) | |
| Obesity status (BMI) | ||
| Normal weight (<25kg/m2) | 13% | 16% |
| Overweight (25-30kg/m2) | 23% | 6% |
| Obese (30-40kg/m2) | 36% | 11% |
| Severe obesity (>40kg/m2) | 62% | 30% |
| Body composition & fat deposition | ||
| Normal VAT | 16% | 10% |
| Elevated VAT | 36% | 11% |
| Normal SAT | 27% | 10% |
| Elevated SAT | 34% | 10% |
| Normal SMI | 30% | 10% |
| Reduced SMI | 26% | 11% |
| Liver fat 5.6-10% | 25% | 7% |
| Liver fat >10% | 56% | 30% |
| Normal pancreatic fat | 29% | 10% |
| Elevated pancreatic fat | 30% | 10% |
| HbA1c range | ||
| Low (<62mmol/mol [T2D]; <38mmol/mol [non-T2D]) | 86% | 30% |
| High (>=62mmol/mol [MODIFY]; >=38mml/mol [non-T2D]) | 67% | 27% |
Probability of NASH (%) under different variable settings in the T2D and non-T2D cohorts.
Figure 4
3.3.2 Impact of HbA1c
Increasing HbA1c status from the low (HbA1c <62 mmol/mol) to high value group (HbA1c >=62mmol/mol) increased the probability of NASH by 22% (24% vs. 46%). (Table 2; Figure 5).
Figure 5
3.3.3 Impact of adipose tissue volumes (VAT and SAT)
We observed a 20% and 7% increase in the probability of NASH when specifying elevated vs. normal measures of VAT and SAT, respectively. (Table 2; Figure 5).
Impact of skeletal muscle area: Reduced SMI decreased the probability of NASH by 4% (30% vs 26%). (Table 2; Figure 5).
3.3.4 Impact of liver and pancreatic fat
Increasing liver fat from 5.6-10% to greater than 10% increased the probability of NASH by 31% (25% vs 56%). Elevated pancreatic fat increased the probability of NASH by 1% (29% vs 30%). (Table 2; Figure 5).
3.3.5 Combination of risk factors
BNs enable a user (e.g., clinician) to specify an individual phenotype, enabling personalised ‘what if’ analysis. For example, a high-risk phenotype with obesity, elevated VAT, elevated liver fat (>10%) and ‘high’ HbA1c had an 86% probability of NASH. In this phenotype, reducing HbA1c to the ‘low’ value reduced the probability of NASH by 29% (67%).
3.4 Cohort without T2D
We observed a 16%, 6%, 11% and 30% probability of NASH under normal weight, overweight, obese, and severe obesity settings. We observed a 1% increase in the probability of NASH when specifying elevated vs normal measures of VAT. Increasing liver fat from 5.6-10% to >10% increased the probability of NASH by 23% (7% vs. 30%). Increasing HbA1c from the ‘low’ <38mmol/mol) to ‘high’ (>38mmol/mol) value reduced the probability of NASH by 1% (10% vs 9%). (Table 2; Figures 4; 5).
Exploring the same high-risk phenotype specified within the T2D cohort, we observed a 30% probability of NASH. Reducing HbA1c lowered the probability of NASH by 3% (27%).
4 Discussion
In this paper, we applied a novel BN approach to demonstrate the mediating influence of type 2 diabetes, particularly determining the impact of poor glycaemic control and higher ectopic fat deposition, focussing on the impact of liver and visceral fat depots, on the increased risk of NASH in people with T2D and those in the general population. Firstly, we found that obesity (versus normal BMI) conferred a 23% increase (within the T2D cohort) and 5% decrease (in the cohort without T2D) in the probability of NASH. However, considering the intrinsic limitations of the BMI, aggregating all measures of body composition (for example, combining adipose tissue and skeletal muscle volumes) into a single measure, this metric assumes that all individuals will have a similar relative proportion of the different biological tissues.
Our work overcomes this limitation by applying BNs to study the association between MR-derived measures of body composition (using regional adipose tissue volumes, VAT and SAT and organ specific fat measurements) and NASH risk, highlighting the independent contribution of fat deposition within visceral and subcutaneous sites. Specifically, within the T2D cohort the probability increase of NASH was more than double under elevated VAT (+20%) than elevated SAT (+7%) conditions. Such finding is similar to that of () who, despite applying different statistical techniques, also observed that higher measures of VAT relative to SAT was predictive of advanced liver fibrosis in people with NAFLD.
VAT area is independently associated with NASH and correlates significantly with histology confirmed NAFLD with significant fibrosis (). Proposed mechanisms behind the association of elevated VAT and NASH include lipotoxicity and an overexpression of proinflammatory cytokines that promote inflammation and fibrosis within the hepatocytes (). Such overexpression of cytokines has been linked to fat deposition within visceral, but not subcutaneous, adipose sites ().
In participants with T2D, our analysis revealed a 22% reduction in the probability of NASH when lowering HbA1c from the ‘high’ (>62mmol/mol) to ‘low’ (<62mmol/mol) range. Furthermore, NASH risk was reduced by 29% when lowering HbA1c in an example high risk phenotype. Importantly, this was achieved without specifying changes to obesity status, liver fat content or body composition. Chronically elevated blood glucose (i.e., glucotoxicity) has been linked to NASH development via its effects on increasing TCA cycle activity and synthesis of Acyl CoA that promote de novo lipogenesis and oxidative stress (). At the time of writing, no FDA-approved pharmacological medications are available for the treatment of NASH. To this end, our findings highlight the potential of glucose lowering therapies for mitigating NASH risk, particularly in high-risk metabolically unhealthy populations or those with overweight/obesity. Interestingly, newer T2D therapies such as GLP1-receptor agonists (liraglutide, semaglutide), novel dual and triple peptides (e.g. tirzepatide) and SGLT2-inhibitors have been shown to decrease levels of ALT and lower liver fat (measured by MRI-PDFF) in people with T2D and areas of fibrosis, ALT/AST and hepatic lipid content in murine NASH models (, ).
Notably, and despite similar measures of BMI and body composition (see Table 1), we found significantly greater measures of liver cT1, liver fat and prevalence of NASH within the T2D cohort. This highlights the clinical need to screen people with T2D for concomitant liver disease and NASH, where critically, we observed similar measures of ALT and significantly greater AST in the non-T2D cohort. Screening for liver disease needs to adopt a multi-modality approach that extends beyond the reliance on circulating biomarkers alone.
Limitations of this study ultimately derive from the fact that NASH is a complex and multifactorial disease that involves numerous mechanisms that are not investigated in our work to date. However, the BN methodology that we use is intrinsically extensible. Future work will seek to broaden the variables included in network construction, such as biochemical pathways associated with hepatocyte injury, for a more comprehensive assessment of NASH risk.
In conclusion, this paper applied Bayesian-networks and probabilistic reasoning to identify populations at a high risk of NASH. We emphasise the role of elevated VAT, liver fat and obesity status in driving the probability of NASH, and these effects are most significant in people with type 2 diabetes highlighting the importance of prevention and good glycaemic management as a potential therapeutic target for addressing the epidemic of NAFLD/NASH.
Statements
Data availability statement
The data analyzed in this study is subject to the following licenses/restrictions: Private data. UK Biobank restrictions. Requests to access these datasets should be directed to tom.waddell@perspectum.com.
Author contributions
TW analyzed the data, built the Bayesian-network, conducted the probabilistic reasoning statistics, and wrote the manuscript. PD and AN supported in revising the manuscript and offered technical assistance in study methodology. HT-B supported in revising the manuscript. DC provided clinical support in building the network, devising probabilistic reasoning questions, revising the manuscript, and producing figure plots. AT provided technical assistance on statistical methodology. AF collected and synthesized genetic data from the UK Biobank. MB assisted with drafting the manuscript, defining project scope, and revising the manuscript for publication. All authors contributed to the article and approved the submitted version.
Funding
The MODIFY study has received funding from the Innovate UK Digital Health Technology Catalyst scheme.
Acknowledgments
We thank the research volunteers for participating in the MODIFY and UK Biobank studies and the Royal Commission for the Exhibition of 1851 for their funding support.
Conflict of interest
TW is a shareholder and an employee at Perspectum. AF is an employee at Perspectum. AT is an employee at Perspectum. HT-B is a shareholder and an employee at Perspectum. MB is a shareholder and an executive at Perspectum.
DC received investigator-initiated research funding from AstraZeneca plc and Novo Nordisk A/S.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1063882/full#supplementary-material
References
1
World Health Organisation. Obesity and overweight fact sheet (2021) (Accessed October 2022).
2
SaeediPPetersohnISalpeaPMalandaBKarurangaSUnwinNet al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843
3
TargherGCoreyKEByrneCDRodenM. The complex link between NAFLD and type 2 diabetes mellitus–mechanisms and treatments. Nat Rev Gastroenterol Hepatol (2021) 18(9):599–612. doi: 10.1038/s41575-021-00448-y
4
YounossiZMGolabiPde AvilaLPaikJMSrishordMFukuiNet al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol (2019) 71(4):793–801. doi: 10.1016/j.jhep.2019.06.021
5
GolabiPOtgonsurenMde AvilaLSayinerMRafiqNYounossiZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (2018) 97(13). doi: 10.1097/MD.0000000000010214
6
YounossiZMGramlichTMatteoniCABoparaiNMcCulloughAJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 2(3):262–5. doi: 10.1016/S1542-3565(04)00014-X
7
TadaTToyodaHSoneYYasudaSMiyakeNKumadaTet al. Type 2 diabetes mellitus: a risk factor for progression of liver fibrosis in middle-aged patients with non- alcoholic fatty liver disease. J Gastroenterol Hepatol (2019) 34):2011–8. doi: 10.1111/jgh.14734
8
El-SeragHBTranTEverhartJE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 126(2):460–8. doi: 10.1053/j.gastro.2003.10.065
9
YounossiZMTampiRPRacilaAQiuYBurnsLYounossiIet al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US. Diabetes Care (2020) 43(2):283–9. doi: 10.2337/dc19-1113
10
WaddellTBagurACunhaDThomaides-BrearsHBanerjeeRCuthbertsonDJet al. Greater ectopic fat deposition and liver fibroinflammation, and lower skeletal muscle mass in people with type 2 diabetes. Obesity (2022). doi: 10.1002/oby.23425
11
LeveltEPavlidesMBanerjeeRMahmodMKellyCSellwoodJet al. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol (2016) 68(1):53–63. doi: 10.1016/j.jacc.2016.03.597
12
ShahRVMurthyVLAbbasiSABlanksteinRKwongRYGoldfineABet al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA study. JACC: Cardiovasc Imaging (2014) 7(12):1221–35. doi: 10.1016/j.jcmg.2014.07.017
13
KwonHKimDKimJS. Body fat distribution and the risk of incident metabolic syndrome: a longitudinal cohort study. Sci Rep (2017) 7(1):1–8. doi: 10.1038/s41598-017-09723-y
14
MiddletonMSHebaERHookerCABashirMRFowlerKJSandrasegaranKet al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology (2017) 153(3):753–61. doi: 10.1053/j.gastro.2017.06.005
15
NoureddinMLamJPetersonMRMiddletonMHamiltonGLeTAet al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (2013) 58(6):1930–40. doi: 10.1002/hep.26455
16
DennisAMouchtiSKellyMFallowfieldJAHirschfieldGPavlidesMet al. A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. Sci Rep (2020) 10(1):1–11. doi: 10.1038/s41598-020-71995-8
17
AnderssonAKellyMImajoKNakajimaAFallowfieldJAHirschfieldGet al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: A multicenter pooled data and meta-analysis. Clin Gastroenterol Hepatol (2021).
18
EichertNGibbonsKHamidADeelchandVWoolgarJSurianoRet al. High prevalence of multi-organ steatosis and fibroinflammation, identified by multi-parametric magnetic resonance imaging, in people with type 2 diabetes. J Hepatol (2022) 77:S433–4. doi: 10.1016/S0168-8278(22)01202-8
19
ImajoKTetlowLDennisAShumbayawondaEMouchtiSKendallTJet al. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. World J Gastroenterol (2021) 27(7):609. doi: 10.3748/wjg.v27.i7.609
20
LiYChenXShenZWangYHuJZhangYet al. Prediction models for acute kidney injury in patients with gastrointestinal cancers: a real-world study based on bayesian networks. Renal failure (2020) 42(1):869–76. doi: 10.1080/0886022X.2020.1810068
21
SelmanBGomesCP. Hill-climbing search. Encyclopedia Cogn Sci (2006) 81:82. doi: 10.1002/0470018860.s00015
22
JungCHRheeEJKwonHChangYRyuSLeeWY. Visceral-to-subcutaneous abdominal fat ratio is associated with nonalcoholic fatty liver disease and liver fibrosis. Endocrinol Metab (2020) 35(1):165–76. doi: 10.3803/EnM.2020.35.1.165
23
YuSJKimWKimDYoonJHLeeKKimJHet al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (2015) 94(48). doi: 10.1097/MD.0000000000002159
24
SchäfflerASchölmerichJBüchlerC. Mechanisms of disease: adipocytokines and visceral adipose tissue–emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2005) 2(6):273–80. doi: 10.1038/ncpgasthep0186
25
Małodobra-MazurMCierzniakAPawełkaDKaliszewskiKRudnickiJDoboszT. Metabolic differences between subcutaneous and visceral adipocytes differentiated with an excess of saturated and monounsaturated fatty acids. Genes (2020) 11(9):1092.
26
GastaldelliACusiK. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep (2019) 1(4):312–28. doi: 10.1016/j.jhepr.2019.07.002
27
ZhangEZhaoYHuH. Impact of sodium glucose cotransporter 2 inhibitors on nonalcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Commun (2021) 5(5):736–48. doi: 10.1002/hep4.1611
28
NewsomePFrancqueSHarrisonSRatziuVVan GaalLCalannaSet al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Alimentary Pharmacol Ther (2019) 50(2):193–203. doi: 10.1111/apt.15316
Summary
Keywords
Ectopic fat deposition, magnetic-resonance imaging, type-2 diabetes, non-alcoholic steatohepatitis, body composition
Citation
Waddell T, Namburete A, Duckworth P, Fichera A, Telford A, Thomaides-Brears H, Cuthbertson DJ and Brady M (2023) Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling. Front. Endocrinol. 14:1063882. doi: 10.3389/fendo.2023.1063882
Received
07 October 2022
Accepted
08 February 2023
Published
22 February 2023
Volume
14 - 2023
Edited by
Claire Joanne Stocker, Aston University, United Kingdom
Reviewed by
Ana Sandoval-Rodriguez, University of Guadalajara, Mexico; Javier Crespo, Marqués de Valdecilla Health Research Institute (IDIVAL), Spain
Updates
Copyright
© 2023 Waddell, Namburete, Duckworth, Fichera, Telford, Thomaides-Brears, Cuthbertson and Brady.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: T. Waddell, tom.waddell@magd.ox.ac.uk
This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.